04/22, GSK, PD-1, Women's cancer
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancerGSKのPD-1阻害薬 JEMPERLI（ドスタルリマブ）は再発性または進行性のミスマッチ修復機構欠損（dMMR）子宮内膜がんの治療薬として加速承認された
04/22, GSK, PD-1, Women's cancer
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer